Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly or Every Two Weeks in Patients With Advanced Solid Malignancies

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis

Inclusion Criteria:

• Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
• Relatively good overall health other than your cancer.

Exclusion Criteria:

• Poor bone marrow function (not producing enough blood cells).
• Serious heart conditions.
• Poor liver or kidney function.